Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, 69437, Lyon cedex 03, France.
Inserm UMR 1033, 69437, Lyon cedex 03, France.
Calcif Tissue Int. 2020 Sep;107(3):203-211. doi: 10.1007/s00223-020-00703-5. Epub 2020 May 18.
Osteoarthritis and sarcopenia are the most frequently described musculoskeletal disorders in older persons but the intertwining of these conditions and of their functional and cellular causes is complex. This narrative review aims to identify the links between osteoarthritis and sarcopenia described 1-in clinical studies, 2-in in vitro studies, and 3-the available treatment strategies for both conditions. Electronic databases were used for the literature search of all studies investigating the relationship between sarcopenia and the presence of concomitant osteoarthritis. This review identified a limited number of clinical and morphometric studies on the complex relationship between osteoarthritis and sarcopenia. Studies present a number of methodological limitations due to definition and assessment of both entities. Low lean mass is one of the main actors of this cross-talk between muscle and bone, and adipose tissue plays a major role that had been underestimated. Bone Morphogenetic Proteins and myostatin pathways are key mediators and play an important role in both muscle and bone homeostasis. Common therapeutic recommendations are still missing. There is a need for good quality prospective studies on concomitant sarcopenia and osteoarthritis, more translational research, and pharmacological and non-pharmacological therapies in order to identify common denominators for the management of sarcopenia, osteoarthritis, and their comorbidities.
骨关节炎和肌肉减少症是老年人最常描述的肌肉骨骼疾病，但这些疾病及其功能和细胞原因的交织是复杂的。本叙述性综述旨在确定 1-临床研究、2-体外研究以及 3-两种疾病现有治疗策略中描述的骨关节炎和肌肉减少症之间的联系。电子数据库用于检索所有研究骨关节炎与同时存在的肌肉减少症之间关系的文献。本综述确定了为数不多的关于骨关节炎和肌肉减少症之间复杂关系的临床和形态计量学研究。由于对这两个实体的定义和评估，研究存在许多方法学上的局限性。低瘦体重是肌肉和骨骼之间这种相互作用的主要因素之一，而脂肪组织起着被低估的主要作用。骨形态发生蛋白和肌肉生长抑制素途径是关键的调节剂，在肌肉和骨骼稳态中发挥着重要作用。仍然缺乏共同的治疗建议。需要进行关于同时患有肌肉减少症和骨关节炎的高质量前瞻性研究，进行更多的转化研究，以及药物和非药物治疗，以便确定肌肉减少症、骨关节炎及其合并症管理的共同标准。
